[253] Vague P, Raccah D, Yuhan Vague I. Hemobiology, vascular disease, and diabetes with special reference to impaired fibrinolysis. Metabolism 1992; 41: 2-6.
[254] Colwell JA, Vascular thrombosis in type II diabetes mellitus. Diabetes 1993; 42: 8-11.
[255] Carter AM, Grant PJ. Vascular homeostasis, adhesion molecules, and macrovascular disease in non-insulin-dependent diabetes mellitus. Diabet Med 1997; 14: 423-32.
[256] Ceriello A, Giuliano D, Quatraro A, Marchi F, Barbanti M, Lefebvre P. Evidence for a hyperglycaemia-dependent decrease of antithrombin III-thrombin complex formation in humans. Diabetologia 1990; 33: 163-7.
[257] Ceriello A. Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabetologia 1993; 36: 1119-25.
[258] Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries SE, Yudkin JS. Determinants of plasminogen activator inhibitor-1 in treated type II diabetes and its relation to a polymorphism in the plasminogen activator inhibitor-1 gene. Diabetes 1995; 44: 37-42.
[259] Tschöpe D, Rösen P, Esser J, Schwippert B, Nieuvenhuis HK, Kehrel B, Gries FA. Large platelets circulation in an activated state in diabetes mellitus. Semin Thrombos Hemost 1991; 17: 433-8.
[260] Tschöpe D, Rösen D, Schwippert B, Gries FA. Platelets in diabetes: the role in the hemostatic regulation in atherosclerosis. Sem Thromb Hemostas 1993; 19: 122-8.
[261] Lupu C, Calb M, lonescu M, Lupu F. Enhanced prothrombin and intrinsic factor X activation on blood platelets from diabetic patients. Thrombos Haemost 1993; 70: 579-83.
[262] Tschöpe D, Rösen P, Gries FA. The role of the megakaryocyte-platelet system for diabetic angiopathy: is metabolic control preventive therapy enough? Thromb Haemorrh Disorders 1992; 6: 1-8.
[263] Tschöpe D, Lampeter E, Schwippert B. Megakaryocytes and platelets in diabetes mellitus. Hämostaseologie 1996; 16: 144-50.
[264] Watanabe J, Wohltmann HJ, Klein RL, Colwell JA, Lopes-Virella MF. Enhancement of platelet aggregation by low density lipoprotein in patients with diabetes mellitus. Diabetes 1988; 37: 1652-7.
[265] Davi G, Catalano J, Averna M, Notarbartolo A, Strano A, Ciabattoni G, Patrono C. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990; 322: 1769-74.
[266] Rauch U, Tschöpe D, Piolot R, Schwippert B, Benthake H, Ziegler D, Gries FA. Circulating inflammatory leukocyte-platelet co-aggregates associated with diabetic cardiovascular autonomic neuropathy [abstract]. Circulation 1995; 92 (suppl): 638.
[267] Tschöpe D, Hesse S, Rauch U, Schwippert B. Monocyteplatelet co-aggregation is associated with low HDL/high triglyceride dyslipoproteinaemia in NIDDM patients [abstract]. Diabetes 1996; 45 (suppl 2): 270A.
[268] Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326: 242-50.
[269] Feener ED, King GL. Vascular dysfunction in diabetes mellitus. Lancet 1997; 350 (suppl 1): SI9-13.
[270] Clarkson P, Celermajor DS, Donald AE, Sampson M, Sorenson KE, Adams M, Yue DK, Betteridge DJ, Deanfield JE. Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels. Am J Coll Cardiol 1996; 28: 573-9.
[271] Cohen RA. Dysfunction of vascular endothelium in diabetes mellitus. Circulation 1993; 87 (suppl 5): 67-76.
[272] Lorenzi M. Glucose toxicity in the vascular complications of diabetes: the cellular perspective. Diab Metab Rev 1992; 8: 85-103.
[273] Laasko M, Lehto S, Penttila J, Pörälä K. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes.Circulation 1993; 88: 1421-30.
[274] Stern MP, Haffner SM. Dyslipidemia In type 2 diabetes: implications for therapeutic intervention. Diabetes Care 1991; 14: 1144-59.
[275] International Task Force for Prevention of Coronary Heart Disease. Recommendations of the European Atherosclerosis Society: Prevention of coronary heart disease: scientific background and new clinical guidelines. Nutr Metab Cardiovasc Dis 1992; 2: 113-56.
[276] Laakso M. Epidemiology of diabetic dyslipidaemia. Diabetes Rev 1995; 3: 408-22.
[277] Manninen V, Tenkanen H, Koskinen P, Huttunen JK, Mäntari M, Heimonen OP, Frick MH. Joint effects of triglycerides and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992; 85: 37-45.
[278] Hokanson JE, Austin MA. Triglyceride is a risk factor for coronary disease in men and women: a meta analysis of population based prospective studies [abstract]. Circulation 1993; 88: 510.
[279] Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation 1979; 60: 473-85.
[280] Patsch JR, Miesenbeck G, Hopferwieser T, Hijhtberger V, Knapp E, Dunn KJ, Gotto AM, Patsch W. Relationship of triglyceride metabolism and coronary artery disease: studies in the postprandial state. Arterioscler Thromb 1992; 12: 1336-45.
[281] Tan KCB, Cooper MB, Ling KL, Griffin BA, Freeman DJ, Packard CJ, Shepherd J, Hales CN, Betteridge DJ. Fasting and postprandial determinants for the occurrence of small dense LDL species in non insulin dependent diabetic patients with and without hypertriglyceridaemia: the involvement of insulin, insulin precursor species and insulin resistance. Atherosclerosis 1995; 113: 273-87.
[282] Taskinen MR, Kuusi T, Helve E, Nikkila K, Yki-Järvinen H. Insulin therapy induces antiatherogenic changes of serum lipoproteins in non-insulin-dependent diabetes. Arteriosclerosis 1988; 8: 168-77.
[283] Winocour PH, Durrington PN, Irhola M, Hillier VF, Anderson DC. The prevalence of hyperlipidaemia and related clinical features in insulin-dependent diabetes mellitus. Q J Med 1989; 70: 265-76.
[284] Haaber AB, Kofoed-Enevoldsen A, Jensen T. The prevalence of hypercholesterolaemia and its relationship with albuminuria in insulin-dependent diabetic patients: an epidemiological study. Diabet Med 1992; 9: 557-61.
[285] Walden CE, Knopp RH, Wahl PW, Beach KW, Strandness E. Sex differences in the effect of diabetes mellitus on lipoprotein, triglyceride and cholesterol concentrations. N Engl J Med 1984; 311: 953-9.
[286] Haffner SM, Mykkanen L, Stern MP, Paidi M, Howard BV. Greater effect of diabetes on LDL size in women than in men. Diabetes Care 1994; 17: 1164-71.
[287] Lopes-Virella MF, Virella G, Cytokines, modified lipoproteins, and arteriosclerosis in diabetes. Diabetes 1996; 45(suppl3):S40-4.
[288] Witztum JL. Role of modified lipoproteins in diabetic macroangiopathy. Diabetes 1997; 46 (suppl 2): S112-14.
[289] Lahdenperä S, Syränne M, Kahri J, Taskinen MR. Regulation of low-density lipoprotein particle size distribution in NIDDM and coronary disease: importance of serum triglycerides. Diabetologia 1996; 39: 453-61.
[290] Taskinen MR, Smith U. Lipid disorders in NIDDM: implications for treatment. J Intern Med 1998; 244: 361-70.
[291] Austin MA, Breslow JL, Hennekens CH, Buring JE, Willet WC, Krause RM. Low density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988; 260: 1917-21.
[292] Graaf J De, Hak-Lemmers HLM, Hectors MPC, Demacker PNM, Hendricks JCM, Stalenhoer AFH. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 1991; 11:298-306.
[293] Stewart MW, Laker MF, Dyer RG, et al. Lipoprotein compositional abnormalities and insulin resistance in type 2 diabetic patients with